Metabolic dysfunction-associated steatohepatitis

This completed Phase 2 study tested whether a combination of two experimental drugs, K-877-ER and CSG452, can improve liver health in adults with nonalcoholic steatohepatitis (NASH) and liver fibrosis. The 228 participants received either the combination or a placebo. The main go…

This study tested an experimental drug called HSK31679 in 186 Chinese adults with non-alcoholic steatohepatitis (NASH), a serious liver condition. Participants took either 80 mg, 160 mg, or a placebo daily for 52 weeks. The goal was to see if the drug could improve liver damage a…

This early-stage trial tested a new drug, LY3849891, in 115 people with fatty liver disease who carry a specific gene variant (PNPLA3 I148M). The main goal was to check safety and how the body processes the drug. Researchers also looked at changes in liver fat and inflammation us…

This study tested three different doses of HPG1860, an experimental oral drug, against a placebo in 89 adults with nonalcoholic steatohepatitis (NASH), a type of fatty liver disease. The main goals were to check safety and see if the drug could lower liver fat content measured by…

This study tested whether analyzing a patient's DNA and RNA could help doctors pick the right drug for inflammatory diseases that don't fit standard categories. 32 adults with at least two affected organs (including skin) received one of six targeted therapies based on their mole…

This study tested a weekly injection called pemvidutide in 212 adults with NASH, a serious liver condition linked to fat buildup. The goal was to see if the drug could reduce liver fat and scarring without worsening the disease. Participants received either the drug or a placebo …

This study tested different doses of vitamin E in 200 adults with nonalcoholic fatty liver disease (NAFLD) to find the best dose for improving liver health. Participants took vitamin E or a placebo for 24 weeks, and researchers measured changes in a key liver enzyme (ALT). The go…

This study tested whether taking phytosterols (plant-based supplements) for 3 months can improve liver health, cholesterol, and insulin levels in people with nonalcoholic fatty liver disease (NAFLD). 27 participants took either phytosterol pills or a placebo. Researchers measured…

This Phase 2 trial tested a drug called DD01 in 67 overweight or obese adults with a type of fatty liver disease (MASLD/MASH). The goal was to see if DD01 could safely reduce liver fat by at least 30% over 48 weeks compared to a placebo. The study is completed, and results will s…

This study tests a medicine called survodutide in adults with overweight or obesity and a liver condition called NASH. Participants receive weekly injections of survodutide or a placebo for about a year, along with diet and exercise advice. The goal is to see if the drug reduces …

This early-phase study tested an oral drug called idebenone in 53 adults with non-alcoholic steatohepatitis (NASH) and mild-to-moderate liver scarring. The main goal was to check safety and tolerability, while also looking for signs that the drug might reduce liver stiffness and …

This study tested whether a combination of two drugs, dasatinib and quercetin, can reduce liver scarring in people with non-alcoholic fatty liver disease (NAFLD) and fibrosis. Thirty adults with biopsy-confirmed liver scarring took either the drug combo or a placebo in cycles ove…

This study tested a drug called BI 770371 in 28 people with compensated cirrhosis caused by MASH, a liver disease linked to metabolism. Participants received either the drug or a placebo as an infusion every 3 weeks for 12 weeks. The main goal was to see how well the drug is tole…

This completed Phase 2 trial tested LAENNEC, a substance made from human placenta, in 49 adults with chronic liver disease. The study aimed to check if the treatment is safe and whether it can improve liver function, measured by a drop in ALT levels. Participants received either …

This phase 2 trial tested elobixibat, a drug that blocks bile acid absorption in the gut, in 47 adults with nonalcoholic fatty liver disease (NAFLD) or its more severe form NASH. Participants received either elobixibat or a placebo for 16 weeks. The main goal was to see if the dr…

This study looked at whether ketotifen, a medicine used for allergies, is safe and helpful for people with non-alcoholic fatty liver disease (NAFLD) who do not have cirrhosis. Sixty adults with NAFLD took part. The main goal was to see if ketotifen could improve liver scarring (f…

This study tested an experimental drug called efinopegdutide in 381 adults with non-alcoholic steatohepatitis (NASH), a serious form of fatty liver disease. The main goal was to see if the drug could help the liver heal (resolve NASH) without making scarring worse. Participants r…

This study tested a new drug called BIO89-100 (Pegozafermin) in 222 adults with NASH, a serious fatty liver disease with liver scarring. Participants received weekly injections of the drug or a placebo for about 6 months. The goal was to see if the drug could reduce liver inflamm…

This pilot study tested a drug called ibutamoren in 12 adults with nonalcoholic fatty liver disease (NAFLD). The goal was to see if it could lower fat in the liver. Participants took the drug for 6 months, and researchers measured liver fat using special MRI scans. The study was …

This study tested whether tranexamic acid, a drug that helps blood clot, can lower the chance of infection after gastrointestinal surgery. Over 3,300 adults at higher risk for complications took part. The goal was to see if the drug reduces surgical site infections compared to a …

This phase 2 trial tested an oral drug called MGL-3196 in 125 adults with non-alcoholic steatohepatitis (NASH), a fatty liver disease that can lead to scarring and liver failure. The main goal was to see if the drug could reduce liver fat measured by MRI after 12 weeks compared t…

This study tested a drug called TRO19622 in 22 adults with NASH, a type of fatty liver disease. Participants took the drug or a placebo for one month to see if it improved liver enzyme levels and was safe. The goal was to gather early information on whether the drug might help co…

This early-stage trial tested a new oral drug called J2H-1702 in 100 healthy men to see if it is safe and how the body processes it. The drug is being developed for non-alcoholic steatohepatitis (NASH), a type of liver disease. The study was completed and used a placebo for compa…

This study tested a new drug called J2H-1702 in 87 adults with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. The goal was to see if the drug is safe and if it can reduce liver fat and scarring after 12 weeks compared to a placebo. Participants were randomly…

This phase 2 trial tested whether semaglutide (a diabetes drug) combined with cilofexor and firsocostat (two experimental liver drugs) can improve liver scarring and resolve NASH in people with cirrhosis. 457 participants with compensated cirrhosis due to NASH were randomly assig…

This study tested whether combining a new liver drug (NNC0194-0499) with semaglutide (a diabetes/weight-loss drug) can reduce liver scarring in people with NASH, a serious fatty liver disease. About 700 adults received weekly injections of either the drug combo, a different combo…

This study tested a drug called BOS-580 (efimosfermin) in 231 obese adults with or at risk for NASH, a serious fatty liver disease. Participants received either the drug or a placebo as a shot under the skin. The main goal was to check safety and side effects. The trial is now co…

This study tested a monthly injection called AZD2693 in 220 adults with non-alcoholic steatohepatitis (NASH) and liver scarring, who carry a specific genetic risk factor. The goal was to see if the drug could reverse liver inflammation and scarring without making it worse. The tr…

This phase 2b trial tested whether saroglitazar magnesium can help people with nonalcoholic steatohepatitis (NASH) and liver fibrosis. 189 adults took either a 2 mg or 4 mg dose of the drug or a placebo daily for several months. The main goal was to see if the drug could resolve …

This study tested a single dose of the experimental drug GSK4532990 in 61 adults with NASH, a type of fatty liver disease. Researchers measured how the drug moves through the body and affects liver proteins, while also checking for safety. The goal is to see if the drug can help …

This study tested an experimental drug called ARO-HSD in 50 healthy volunteers and people with NASH, a serious fatty liver disease. The main goal was to check safety and how the drug moves through the body. It's an early step to see if ARO-HSD might be a future treatment for NASH…

This study tested a drug called cotadutide in 54 adults with a type of fatty liver disease that includes liver scarring but not cirrhosis. Participants received either the drug or a placebo as a daily injection. The main goal was to check safety and tolerability, with results hel…

This study is testing a portable, non-invasive breath analyzer that measures tiny particles in exhaled breath to screen for conditions like type 2 diabetes, liver disease, kidney disease, and lung disease. Researchers will enroll healthy volunteers and people with known diagnoses…

This study looked at how well a new, quick finger-prick test (LumiraDx CRP) measures CRP levels compared to a standard lab test. CRP is a marker of infection, inflammation, or tissue injury. 79 adults with symptoms of these conditions took part. The goal was to see if the new tes…

This study looked at over 1,200 adults with metabolic fatty liver disease (MASLD) to see if a new digital test, called FibroNest Ph-FCS, can predict who will develop serious liver complications. The test uses computer analysis of standard liver biopsy images to measure scarring. …

This study tested a new, fully automated MRI technique to diagnose liver fibrosis and inflammation without needing a needle biopsy or contrast dye. Researchers scanned 200 adults with chronic liver disease and compared the MRI results to standard biopsy findings. The goal is to p…

This study tested whether a special ultrasound, called ShearWave Elastography, can measure liver stiffness without needing a needle biopsy. Over 1,200 adults with chronic liver disease, liver transplants, or heart failure had a quick scan during a regular clinic visit. The goal w…

This study tested a new ultrasound software that measures liver fat in children and teens aged 5 to 21 with or at risk for fatty liver disease. Researchers compared the ultrasound results to standard MRI scans to see if the ultrasound could accurately detect liver fat. If it work…

This study by Mayo Clinic tested whether analyzing chemicals in a person's breath could help diagnose or predict the course of liver disease, liver cancer, and COVID-19. Researchers collected breath samples from 46 participants and looked for unique patterns of volatile organic c…

This study compared two methods of taking a liver tissue sample: one using an endoscope with ultrasound (EUS) and the other using a needle through the skin (percutaneous). Researchers wanted to see which method provides better samples for diagnosing liver disease. The trial invol…

This study tested a new blood test called LLIFT to see if it can accurately diagnose fatty liver disease and its severe form, NASH, without needing a liver biopsy. Researchers enrolled 158 people at high risk for metabolic syndrome. The LLIFT test combines patient information lik…

This early study tested a new radioactive tracer called 18F-FDS in 16 people with suspected bacterial or fungal infections. The tracer is designed to light up infection sites on PET/CT scans, helping doctors see exactly where an infection is. The goal was to check how the tracer …

This study looked at two different needle sizes used to take liver tissue samples during an endoscopy procedure. The goal was to see which needle gives better samples for diagnosing liver disease. 82 patients with unexplained high liver enzymes took part, and each had samples tak…

This study tested how well a special MRI scan called LiverMultiScan can measure liver fat, iron, and scarring. 61 adults with various liver diseases had up to 6 scans on different machines. The goal was to see if the results are consistent when repeated on the same scanner or on …

This study looked at whether two blood tests, eLIFT and FibroMeter, can accurately detect liver fibrosis (scarring) in people with type 2 diabetes. The researchers compared these blood tests to standard methods like FibroScan and liver biopsy. The goal is to find a simpler, less …

This study tested whether a personalized home exercise program (walking three times a week and strength training with elastic bands twice a week) could improve fitness and strength in 30 adults waiting for a liver transplant. The goal was to see if better fitness before surgery c…

This study tested whether using a lidocaine spray along with a low dose of a muscle relaxant (cisatracurium) can make placing a breathing tube easier and safer during ERCP, a procedure for bile duct problems. 186 adults with liver issues were randomly assigned to receive either t…

This study tested a 12-week online mind-body program for adults with chronic conditions like heart failure, cancer, and liver disease. The program included mindful movement, meditation, breathwork, and coping skills. Researchers measured changes in anxiety, depression, fatigue, a…

This completed study looked at how the social networks of caregivers affect their stress and health when caring for someone with an inherited disease. Researchers surveyed over 680 participants, including family members and formal caregivers, to understand caregiving burden and s…

This completed Phase 1 study looked at how the drug tirabrutinib is processed in people with mild, moderate, or severe liver impairment compared to healthy volunteers. Forty participants took a single oral dose, and researchers measured drug levels and safety. The goal was to und…

This study looked at liver fibrosis (scarring) in 127 HIV patients who had high liver enzymes while on antiretroviral therapy. Participants underwent tests like liver biopsy, ultrasound, and CT scans to measure liver damage. The goal was to understand how common and severe liver …

This study looked at how the body processes a single dose of the drug etavopivat in people with mild, moderate, or severe liver disease compared to those with healthy livers. 48 adults took part. The goal was to understand how liver function affects drug levels and safety, which …

This completed study observed 40 people with type 2 diabetes to find blood markers that could identify those at risk for a serious liver condition called NASH. Researchers measured liver stiffness and calculated scores like FIB-4 and ELF to see which patients might have liver sca…

This study looked at a new method to measure pressure in the liver's blood vessels during an endoscopic ultrasound. Researchers tested it in 100 adults with liver disease to see if it is safe and works well. The goal was to gather information, not to treat the disease.

This completed study collected blood or saliva samples from 213 people with rare liver diseases to extract and store their DNA. The goal was to create a genetic resource that scientists can use in future studies to explore the causes, biomarkers, and genetic factors of these cond…

This study looked at how a single dose of MY008211A tablets moves through the body in people with different levels of liver function. 24 adults (some with liver problems, some without) took part. The goal was to understand safety and how the liver affects drug levels, not to trea…

This study looked at 315 HIV-positive adults to build models that predict fatty liver disease and liver scarring. Researchers used ultrasound and FibroScan tests to track liver changes over time. The goal was to better understand and identify liver problems early in people living…

This completed Phase 1 study looked at how the experimental cholesterol-lowering drug enlicitide is processed in the body of people with mild or moderate liver impairment compared to healthy volunteers. Twenty participants received a single oral dose, and researchers measured dru…

This study looked at how the drug LY3502970 enters the bloodstream and leaves the body in people with different levels of liver function. 29 participants, including healthy volunteers and those with mild to severe liver impairment, took a single dose. The goal was to understand d…

This study looked at how the drug MCI-186 (also called edaravone) behaves in people with mild or moderate liver impairment compared to those with healthy livers. Twenty-two participants received a single dose of the drug. The goal was to see if liver problems affect how the drug …

This study followed over 7,300 people with nonalcoholic fatty liver disease (NAFLD) and its more severe form, NASH, in regular doctor visits. Researchers aimed to understand how the disease progresses and what treatments doctors are using, since no drugs are officially approved f…

This study tested a new ultrasound technique called ARFI to measure liver stiffness in 109 people, including healthy volunteers and patients with liver conditions. The goal was to understand normal stiffness values and how they change with disease or treatment. This is an observa…

This study tested whether a pop-up alert in the electronic medical record could help doctors remember to refer patients with fatty liver disease (NASH) to a liver specialist. Thirty doctors from internal medicine, family medicine, and endocrinology took part. The goal was to see …

This completed study used leftover liver tissue from 36 adults who had surgery to create lab models of early infection. Researchers want to learn how bacteria and viruses first take hold in the liver, which could lead to new ways to prevent or treat serious bloodstream infections…

This study looked at how a single dose of the drug AZD2693 moves through the body in people with liver impairment compared to healthy volunteers. Researchers measured drug levels in the blood to understand safety and processing differences. A total of 35 adults took part. The goa…

This study looked at how the body processes a drug called ESK001 in people with different levels of liver function. Researchers gave a single dose to 32 adults, including healthy volunteers and those with mild, moderate, or severe liver impairment. The goal was to measure drug le…

This completed observational study at Uşak University examined 150 adults hospitalized in the endocrinology department. Researchers measured breathing, muscle strength, pain, fatigue, sleep quality, physical activity, balance, and nerve function. The goal was to better understand…

This early-stage trial looked at how a single 50mg dose of pyroglutamate rongliflozin capsules behaves in 32 adults with mild or moderate liver damage and type 2 diabetes, compared to healthy volunteers. Researchers measured drug levels in the blood and tracked side effects to un…

This completed Phase 1 study looked at how moderate and severe liver impairment changes the way the body handles a single dose of palovarotene, compared to healthy people. Thirty-one participants were split into three groups based on liver function and received up to 10 mg of the…

This early-stage study tested a single 4 mg dose of the drug elpipodect (MK-8189) in 14 people—some with mild or moderate liver problems and some healthy. Researchers measured how much drug stayed in the blood and for how long. The goal was to see if liver impairment changes drug…

This study looked at how people with chronic liver disease (like hepatitis B, C, or fatty liver) respond to COVID-19 vaccines. About 233 adults had three visits over a year to check their immune response and see if they got COVID-19. The goal was to understand if liver disease af…

This study looked at 10,000 older adults (age 60+) with fatty liver disease to find out what increases their risk for serious liver problems like scarring, cirrhosis, or liver cancer. Researchers used medical records and yearly check-ups to build a computer model that predicts th…

This study compared two procedures for getting a liver biopsy and measuring liver pressure in people with chronic liver disease or cirrhosis. One method uses a scope through the mouth (endoscopic ultrasound), the other goes through a vein in the neck (transjugular). The goal was …

This study tested whether a mobile health app called EL-FIT could help people with nonalcoholic steatohepatitis (NASH) exercise safely at home. Seventeen adults with NASH used the app and a Fitbit to do daily exercise as they wished. The main goal was to see if it was feasible an…

This study compared how patients feel about two ways to take a small sample of liver tissue: one using a needle through the skin (percutaneous) and another using a thin tube through the mouth (EUS-guided). 102 adults with chronic liver disease were randomly assigned to one method…

This study examined medical records of 263 adults with NASH to see how factors like age, other health problems, and medications relate to the severity of liver scarring. The goal was to identify which patients are at higher risk for advanced fibrosis. The findings may help doctor…

This study looked at whether a computer analysis of liver biopsy images (called FibroNest Ph-FCS) can predict future liver complications in people with a type of fatty liver disease called MASLD. Researchers reviewed medical records from 1,578 patients to see if the digital score…

This study looked at how the body handles a single shot of fazirsiran in 34 people with mild, moderate, or severe liver problems, compared to those with healthy livers. Participants were followed for 6 months after the injection. The goal was to measure drug levels and check for …

This study used online questionnaires to understand how well healthcare providers and people with or at risk for MASH (a liver disease) understand the links between MASH and heart, kidney, and metabolic conditions. About 1,330 participants completed the 25-minute survey. The goal…

This study looked at how the body processes a single dose of the drug AMG 133 in people with different levels of liver impairment compared to those with healthy livers. Thirty-six adults took part, and researchers measured drug levels in the blood and checked for side effects. Th…

This study tested new MRI and MRE techniques that let children breathe normally during scans, instead of holding their breath. The goal was to measure liver fat and stiffness more comfortably and accurately in kids with fatty liver disease. 135 children aged 6-17 took part, and t…

This study looked at how the drug varegacestat moves through the body in people with liver problems compared to healthy people. About 35 adults took a single dose, and researchers measured drug levels and side effects. The goal was to understand if liver impairment changes how th…

This study looked at how the drug BPN14770 is handled by the body in people with mild, moderate, or severe liver impairment compared to healthy people. A total of 32 adults took a single dose of the drug. Researchers measured drug levels in the blood and checked for side effects.…

This completed Phase 1 study looked at how the drug MK-8527 moves through the body in people with mild or moderate liver impairment compared to healthy volunteers. Researchers measured drug levels in the blood over time to understand how liver function affects the drug. The study…

This early-stage study tested the safety of a new drug called ACT500 in 72 healthy Chinese adults. Participants received either the drug or a placebo, and researchers monitored side effects and how the drug moved through the body. The goal was not to treat disease but to gather e…

This study tested whether video-based education helps liver transplant patients adapt to their disease and use medications correctly. 90 adult patients were split into three groups: two received different video trainings, and one got standard care. Researchers measured adaptation…

This study tested a single injection of a new drug (NNC0194-0499) for non-alcoholic fatty liver disease in 33 people with various degrees of liver impairment and healthy volunteers. The goal was to see how the liver processes the drug and whether it is safe. Results will help det…

This study looks at how moderate liver problems change the way the body handles sevabertinib, an experimental cancer drug for tumors with HER2 mutations. About 20 people—10 with liver impairment and 10 healthy volunteers—will take a single dose and have their blood levels measure…

This completed Phase 1 study looked at how the drug HRS-5965 behaves in people with mild or moderate liver impairment compared to those with normal liver function. Twenty-four adults took a single 50 mg dose of the drug. The goal was to measure drug levels in the blood and check …

This completed Phase 1 study looked at how the drug bulevirtide (Hepcludex) behaves in the body of people with normal liver function and those with liver impairment. Researchers measured drug levels in the blood and how quickly it is cleared. The study involved 74 participants an…

This study tested a new ultrasound feature that measures liver fat and compared it to the standard MRI method. About 60 adults with or at risk for fatty liver disease had two ultrasounds and one MRI. The goal was to see if the ultrasound could accurately estimate liver fat, which…

This completed Phase 1 study looked at how the drug golcadomide is processed in the body of people with moderate or severe liver impairment compared to healthy volunteers. 29 adults received a single dose, and researchers measured drug levels and safety. The goal is to understand…

This study looked at how camlipixant, an experimental drug for chronic cough, behaves in people with liver problems compared to healthy volunteers. 32 adults aged 18-75 took part to see if liver impairment changes drug levels or safety. The goal is to help doctors decide the righ…

This study looked at different ultrasound techniques to measure liver stiffness in 72 adults with chronic liver disease. The goal was to see how newer methods compare to an established one. No treatments or interventions were given; it was purely a comparison of measurement tools…

This study looked at how paracetamol (a common painkiller) is processed in the body after major liver surgery. Researchers measured paracetamol levels in the blood over five days in 90 patients who had different amounts of liver removed. The goal was to understand if patients wit…

This study looked at how a single dose of the antifungal drug fosmanogepix is processed in the bodies of 28 adults with varying degrees of liver impairment. Participants took one pill by mouth, and researchers measured drug levels in the blood over time. The goal was to see if li…

This early-stage trial tested the safety and tolerability of a single dose of J2H-1702 in 16 healthy women. The drug is being developed for non-alcoholic steatohepatitis (NASH), a serious liver condition. Researchers measured how the body processes the drug and its effects, but t…

This study tests how the experimental drug cagrilintide, being developed for weight management, is processed by the body in people with different levels of liver function. It involves 32 participants, including those with liver impairment and healthy volunteers. The goal is to se…

This study looked at how the drug divarasib is processed in the bodies of 31 people with different levels of liver function, from healthy to severely impaired. Participants received a single dose, and researchers measured drug levels in the blood over time. The goal was to unders…

This study looks at how the drug BI 1015550 is absorbed and processed in the blood of people with mild or moderate liver problems compared to those with healthy livers. About 28 adults took a single dose and had blood samples taken over several days. The goal is to understand if …

This study tested a new drug called AZD4076 in 40 healthy men to see if it is safe and how the body processes it. The drug is being developed for non-alcoholic steatohepatitis (NASH), a serious liver condition. This is an early, first-in-human trial, so it focused only on safety …

This completed Phase 1 study tested a single 50 mg dose of the drug KP-001 in 24 adults, some with healthy livers and others with different levels of liver impairment. The goal was to see how liver function affects the drug's levels and safety in the body. Results could help guid…

This study looked at how different levels of liver impairment affect the way the body processes a single dose of the drug evobrutinib. Twenty-four participants with either normal liver function or mild to moderate liver impairment took one dose of the drug. Researchers measured d…

This study looked at how the drug efinopegdutide behaves in people with moderate to severe liver damage compared to healthy people. A total of 22 adults took a single dose, and researchers measured drug levels and safety. The goal was to understand dosing needs for patients with …

This study looked at how the drug olpasiran is processed by the body in people with mild, moderate, or severe liver problems compared to those with healthy livers. A total of 25 adults took a single dose of the drug. The goal was to understand safety and how the liver affects dru…

This completed Phase 1 study looked at how a single dose of the drug AZD5004 moves through the body in people with mild, moderate, or severe liver impairment compared to healthy volunteers. The goal was to measure drug levels and check safety. 33 adults aged 18-80 took part. The …

This study looked at how a single dose of the drug repotrectinib stays in the blood of people with moderate or severe liver impairment compared to healthy volunteers. 18 adults took part to help understand if liver problems change drug levels. The results will guide dosing for pa…

This study looked at how the drug AZD2389 behaves in people with liver impairment compared to healthy volunteers. 35 adults took a single dose, and researchers measured drug levels in the blood to check safety and processing. The goal is to understand if liver problems change how…

This completed Phase 1 study looked at how a single 0.5 mg dose of the drug cenerimod is processed in 24 people — some with mild or moderate liver impairment and some healthy. The goal was to see if liver problems change drug levels or safety. Participants were monitored for side…

This completed Phase 1 study looked at how olomorasib, an oral drug, enters the bloodstream and leaves the body in people with mild, moderate, or severe liver impairment compared to healthy volunteers. 46 participants received a single dose. The goal is to understand if liver fun…

This study looked at how the drug fexinidazole, used for sleeping sickness, is processed by the body in people with mild or moderate liver impairment compared to those with normal liver function. Twenty-one adults took a single 1200 mg tablet, and researchers measured drug levels…

This early-stage study looked at how a single dose of venglustat is processed in people with mild, moderate, or severe liver problems compared to healthy adults. Twenty-six participants received one tablet and were monitored for about three weeks. The goal was to see if liver fun…